anthera pharmaceuticals inc
(ANTH:NASDAQ GM)

Executive Profile*

Background*

Dr. James E. Pennington, Jim, M.D. served as Senior Clinical Fellow of Anthera Pharmaceuticals Inc. from May 1, 2010 to May 2010 and also served as its Executive Vice President and Chief Medical Officer from March 20, 2007 to May 1, 2010. Dr. Pennington was a Member of Anthera's senior management team and was responsible for providing medical and scientific guidance in the clinical development of its pipeline products. He has over 20 years of experience in the pharmaceutical ... industry. He served as Chief Medical Officer and Executive Vice President of CoTherix Inc., since February 2004. From January 2001 to January 22, 2004, Dr. Pennington served as an Executive Vice President of Medical and Scientific Affairs of InterMune Inc. From June 1999 to January 2001, Dr. Pennington served as Senior Vice President of Research, Development and Clinical Affairs of Alpha Therapeutics Corp. From October 1997 to February 1999, Dr. Pennington served as Senior Vice President of Clinical Research at Shamen Pharmaceuticals Inc. From July 1994 to October 1997, he served as Vice President of Biological Clinical Research at Bayer Corporation. He serves as Chairman of Clinical Advisory Board at Trius Therapeutics, Inc. He serves as a Member of Development Advisory Board of Biolex Therapeutics, Inc. (formerly Biolex Incorporated). From September 1986 to June 1994, Dr. Pennington served as a Director of Bayer Corporation. Prior to joining the pharmaceutical industry, Dr. Pennington spent 12 years as a member of the Harvard Medical School faculty. He holds the position of Clinical Professor of Medicine at the University of California, San Francisco and is Board Certified in Internal Medicine and Infectious Disease. Dr. Pennington holds a B.A. in General Science from the University of Oregon and an M.D. from the University of Oregon Medical School and is Board Certified in internal medicine and infectious diseases.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
ANTH:US	$0.58 USD	-0.028

COMPETITOR COMPENSATION